We use cookies to personalise site content, social media features and to analyse our traffic. We also share information about your use of this site with our advertising and social media partners.
The guidance replaces the 30 October 2017 draft guidance of the same name and describes the administrative steps #FDA will take to either Refuse to Accept (RTA) or file a request for an evaluation of automatic class III designation (De Novo request).